Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.24 USD | +1.92% |
|
-13.47% | -9.79% |
06-11 | MaxCyte CEO Maher Masoud buys 100,000 shares | AN |
06-11 | Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 95.12 | 556.7 | 1,034 | 541 | 466 | 435.6 | - | - |
Enterprise Value (EV) 1 | 83.31 | 526.9 | 778.7 | 313.6 | 297.7 | 285.9 | 315.6 | 337.1 |
P/E ratio | -7.21 x | -42.4 x | -48.6 x | -23 x | -12.1 x | -9.13 x | -9.9 x | -13.3 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 4.4 x | 21.3 x | 30.5 x | 12.2 x | 11.3 x | 12 x | 9.34 x | 6.66 x |
EV / Revenue | 3.85 x | 20.1 x | 23 x | 7.09 x | 7.21 x | 7.85 x | 6.77 x | 5.15 x |
EV / EBITDA | -7.06 x | -52.6 x | -44.7 x | -12.7 x | -6.75 x | -5.74 x | -7.43 x | -14.5 x |
EV / FCF | - | - | -53.7 x | -9.43 x | -11.7 x | -4.88 x | -5.4 x | -7.22 x |
FCF Yield | - | - | -1.86% | -10.6% | -8.53% | -20.5% | -18.5% | -13.9% |
Price to Book | - | - | - | - | - | 2.15 x | 2.42 x | 2.51 x |
Nbr of stocks (in thousands) | 57,389 | 77,185 | 101,203 | 102,230 | 103,860 | 104,544 | - | - |
Reference price 2 | 1.658 | 7.213 | 10.21 | 5.292 | 4.487 | 4.167 | 4.167 | 4.167 |
Announcement Date | 21/04/20 | 20/04/21 | 22/03/22 | 15/03/23 | 12/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 21.62 | 26.17 | 33.89 | 44.26 | 41.29 | 36.42 | 46.63 | 65.45 |
EBITDA 1 | -11.81 | -10.01 | -17.42 | -24.79 | -44.13 | -49.86 | -42.44 | -23.33 |
EBIT 1 | -12.42 | -11.06 | -18.19 | -27.36 | -48.3 | -57.16 | -51.62 | -40.28 |
Operating Margin | -57.44% | -42.25% | -53.66% | -61.82% | -116.98% | -156.97% | -110.69% | -61.54% |
Earnings before Tax (EBT) 1 | -12.9 | -11.82 | -19.08 | -23.57 | -37.92 | -47.23 | -42.12 | -33.84 |
Net income 1 | -12.9 | -11.82 | -19.08 | -23.57 | -37.92 | -48.67 | -44.97 | -33.86 |
Net margin | -59.64% | -45.15% | -56.3% | -53.25% | -91.85% | -133.65% | -96.43% | -51.73% |
EPS 2 | -0.2300 | -0.1700 | -0.2100 | -0.2300 | -0.3700 | -0.4565 | -0.4209 | -0.3127 |
Free Cash Flow 1 | - | - | -14.51 | -33.26 | -25.39 | -58.6 | -58.48 | -46.7 |
FCF margin | - | - | -42.82% | -75.14% | -61.49% | -160.92% | -125.41% | -71.35% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Announcement Date | 21/04/20 | 20/04/21 | 22/03/22 | 15/03/23 | 12/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2020 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 10.89 | 10.15 | 11.59 | 9.608 | 10.64 | 12.42 | 8.576 | 9.043 | 8.004 | 15.67 | 11.34 | 7.971 | 8.383 | 8.908 | 10.1 | 10.64 |
EBITDA 1 | - | -4.538 | -3.672 | -8.191 | -7.085 | -5.842 | -12.22 | -12.05 | -12.87 | -6.993 | -11.16 | -12.82 | -12.8 | -13.14 | -11.35 | -11.01 |
EBIT 1 | - | -4.955 | -4.159 | -8.739 | -7.712 | -6.75 | -13.18 | -13.07 | -13.95 | -8.095 | -12.28 | -15.17 | -14.88 | -14.92 | -14.22 | -13.9 |
Operating Margin | - | -48.81% | -35.89% | -90.96% | -72.46% | -54.33% | -153.65% | -144.58% | -174.31% | -51.67% | -108.23% | -190.26% | -177.49% | -167.46% | -140.86% | -130.62% |
Earnings before Tax (EBT) 1 | - | - | -4.067 | -8.26 | -6.434 | -4.809 | -10.88 | -10.51 | -11.25 | -5.277 | -9.526 | -12.47 | -12.26 | -12.55 | -12.72 | -12.38 |
Net income 1 | - | -4.874 | -4.067 | -8.26 | -6.434 | -4.809 | -10.88 | -10.51 | -11.25 | -5.277 | -9.526 | -13.18 | -12.95 | -13.02 | -12.66 | -12.38 |
Net margin | - | -48.01% | -35.1% | -85.97% | -60.45% | -38.71% | -126.88% | -116.25% | -140.57% | -33.68% | -83.99% | -165.4% | -154.53% | -146.14% | -125.39% | -116.3% |
EPS 2 | -0.1000 | -0.0500 | -0.0400 | -0.0800 | -0.0600 | -0.0500 | -0.1100 | -0.1000 | -0.1100 | -0.0500 | -0.0900 | -0.1229 | -0.1200 | -0.1200 | -0.1175 | -0.1175 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 21/09/20 | 22/03/22 | 09/05/22 | 10/08/22 | 09/11/22 | 15/03/23 | 10/05/23 | 09/08/23 | 08/11/23 | 12/03/24 | 07/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | 11.8 | 29.8 | 255 | 227 | 168 | 150 | 120 | 98.5 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | -14.5 | -33.3 | -25.4 | -58.6 | -58.5 | -46.7 |
ROE (net income / shareholders' equity) | - | - | - | - | - | -21.6% | -20.6% | -13.4% |
ROA (Net income/ Total Assets) | - | - | - | - | - | -18.5% | -17.4% | -11.1% |
Assets 1 | - | - | - | - | - | 262.8 | 258.5 | 304.6 |
Book Value Per Share 2 | - | - | - | - | - | 1.940 | 1.720 | 1.660 |
Cash Flow per Share 2 | - | - | - | - | - | -0.2300 | -0.2400 | -0.0700 |
Capex 1 | 1.27 | 2.07 | 3.83 | 18.5 | 3.7 | 4.77 | 5.52 | 6.24 |
Capex / Sales | 5.88% | 7.92% | 11.31% | 41.75% | 8.96% | 13.11% | 11.84% | 9.54% |
Announcement Date | 21/04/20 | 20/04/21 | 22/03/22 | 15/03/23 | 12/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.37% | 216B | |
+10.21% | 189B | |
+28.22% | 153B | |
+34.42% | 114B | |
+0.99% | 63.2B | |
+19.21% | 54.78B | |
+0.13% | 48.47B | |
-4.16% | 38.88B | |
+2.39% | 36.14B |
- Stock Market
- Equities
- MXCT Stock
- MXCT Stock
- Financials MaxCyte, Inc.